Recovery from Injury
Soft-tissue and tendon recovery is where peptide therapy has the most enthusiastic community evidence — and the smallest gap between enthusiasm and the human data. The two core peptides in this protocol (BPC-157 and TB-500) have rodent and in-vitro evidence for tissue repair, but essentially no human RCT data for the indications they're used for. Be honest with yourself about that.
This protocol assumes you have a real injury diagnosis from a clinician (imaging if structural, exam if soft-tissue) and that rehab/physical therapy is part of your plan. Peptides are an adjunct to a real recovery plan, not a substitute for one. If you're working through a partial tear that needs surgical evaluation, address that first — peptides don't fix mechanical disruption.
The phases mirror the natural injury timeline: acute stabilization, subacute tissue repair, chronic strengthening. Each phase has decision criteria so you know when to advance, when to pivot, and when to stop.
Phases
Phase 1 — Acute stabilization
weeks 1-2BPC-157 alone for the first 2 weeks. Mechanism: anti-inflammatory + angiogenic effects in rodent models; theoretical early-tissue stabilization. Starting with BPC alone (not the pair) lets you read the signal and confirm tolerability before layering TB-500 in Phase 2.
- BPC-157500 mcg · daily · evening
Starting dose is 250-500mcg daily SubQ near the injury site (or systemic SubQ if the site doesn't allow local injection). Evening timing helps with overnight tissue-repair cycles.
What “working” looks like
Pain reduction of ≥30% by week 2. Decreased swelling and warmth at the site. Earlier-morning range-of-motion improvements.
Decision criteria
If pain ↓ ≥30% by week 2: advance to Phase 2. If pain unchanged or worse by week 2: STOP. Reassess with your clinician — this may indicate a structural issue (partial tear, ligament involvement) that needs imaging or surgical evaluation, not peptides.
Labs to pull
- Baseline hs-CRP — establish inflammation baseline before starting
- CBC + complete metabolic panel — standard pre-intervention screen
Phase 2 — Subacute tissue repair
weeks 2-6Add TB-500. Community-standard "Wolverine" pairing — BPC-157 and TB-500 are mechanism-complementary (BPC drives angiogenesis + collagen synthesis; TB-500 drives actin-dependent cell migration). The pair is co-injectable because both peptides are pH-compatible. Evidence-honest framing: TB-500's human data is essentially absent; the pairing has no RCT of its own. Continue rehab/PT throughout.
- BPC-157500 mcg · daily · evening
Continue Phase 1 dose. Maintaining the BPC layer is what the TB-500 addition is built on.
- TB-5002 mg · twice weekly · evening
2mg SubQ twice weekly. Pairs cleanly with BPC-157 (same injection if site allows; same evening timing).
What “working” looks like
Range of motion approaching pre-injury baseline by week 6. Strength testing on the affected side at ≥70% of unaffected side. Functional milestones from your PT progressing on schedule.
Decision criteria
If functional milestones progressing: advance to Phase 3 OR taper out (if recovery is already at ≥90% baseline). If milestones stalled by week 6: pause the protocol, return to your clinician + PT for re-evaluation. Stalled recovery is a clinical question, not a dosing question.
Phase 3 — Chronic strengthening
weeks 6+Add GHK-Cu for collagen-synthesis support during the rebuild phase. GHK-Cu has decent human evidence for topical/cosmetic skin use and theoretical tissue-rebuild support via copper-mediated collagen synthesis. For injectable tissue-repair use specifically the evidence is Tier 3. Use only if rebuild feels slow vs your pre-injury baseline.
- BPC-157500 mcg · daily · evening
Maintain through chronic strengthening. Taper out once rebuild is complete (see decision criteria).
- TB-5002 mg · twice weekly · evening
Continue Phase 2 pairing. Same taper plan as BPC-157.
- GHK-Cu2 mg · MWF · evening
2mg SubQ on Mon/Wed/Fri. Collagen-synthesis support for the rebuild layer. Skip this peptide if Phase 2 already had you at functional baseline.
What “working” looks like
Full pre-injury range of motion + strength on the affected side. Pain-free under normal load. Functional return to sport/activity. This is the maintenance/exit state.
Decision criteria
If at full pre-injury baseline by week 10-12: taper all peptides over 2 weeks. If still rebuilding past week 12: continue with periodic reassessment (every 4 weeks). If pain returns at any point: STOP, return to clinician.
Cautions
- Rule out structural disruption before starting. If you have a suspected partial or full tear, get imaging (MRI or ultrasound) and surgical consultation before considering peptides. Peptides do not fix mechanical disruption — they may mask symptoms that need surgical intervention.
- Peptides are an adjunct to rehab/physical therapy, not a substitute. Returning to full activity without progressive loading and PT puts you at high re-injury risk regardless of what peptides you take.
- Athletes subject to WADA or sport-specific anti-doping: BPC-157 is on the WADA prohibited list under S0 (Non-Approved Substances). TB-500 falls under S2 (Peptide Hormones, Growth Factors). Both are banned in and out of competition. Detection windows extend beyond plasma clearance via the Athlete Biological Passport.
- Post-surgical recovery: do not start peptides until your surgeon has cleared you for adjunct interventions. Surgical sites have different healing requirements than soft-tissue or tendon strains; growth-factor stimulation on a recovering surgical site is uncharacterized.
- Cancer history: BPC-157 and TB-500 both upregulate growth-factor and angiogenic signaling in vitro. If you have an active or recent cancer diagnosis, this protocol is contraindicated — work with your oncology team on recovery support that does not stimulate these pathways.
Discuss with your clinician
- Bring your imaging results (if any) and your PT plan to the conversation. Peptide adjunct only makes sense in the context of a real diagnosis + rehab plan.
- Ask your clinician about the WADA status of these peptides if you compete in any sport that drug-tests, even at amateur or masters level.
- If you have a cancer history (active or remission), explicitly raise this protocol with your oncology team before starting — the growth-factor mechanisms overlap with pathways some cancers use.
- If you are on blood thinners, NSAIDs, or anti-inflammatory regimens for unrelated reasons, ask about timing of peptide injections relative to those medications.
- Repeat hs-CRP at week 4 — establishing whether systemic inflammation has resolved is part of the decision to taper.
Evidence summary
Tier 3 protocol overall. The core pairing (BPC-157 + TB-500) is the most-used soft-tissue community protocol but has essentially no human RCT support — rodent and veterinary evidence dominate. GHK-Cu's Tier 2 evidence base is for topical/cosmetic skin use; the injectable tissue-repair indication is Tier 3. The mechanistic case for each component is coherent; the protocol-as-a-whole rating reflects the human-outcome evidence gap, not the mechanistic gap.
Often combined with
- Energy & Vitality
People recovering from injury often present with low energy as a secondary symptom (sleep disruption from pain, reduced activity, inflammatory state). The cofactor + mitochondrial layers of the Energy protocol stack cleanly with this one — no peptide conflicts, complementary mechanisms.
Ready to add this protocol to your stack?
Phase 1 entries start today; later phases are future-dated and ready to edit.